Condition: Hematopoietic Stem Cell Transplantation (HSCT) · Acute Myeloid Leukemia (AML) · Leukemias, Acute Myeloid · Sponsor: Yigeng Cao,MD,PhD
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.
This description comes directly from the study's public registry record.
Yigeng CAO, MD,PhD · +8618622477066 · caoyigeng@ihcams.ac.cn
Hui Geng · +8618729989935 · gh0227@sina.com
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Qinghai University | Xining, Qinghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07205523